Advise patients to inform their health care providers of the following: History of QT prolongation; recent acute myocardial infarction; uncompensated heart failure; prescription of other drugs that have demonstrated QT prolongation; risk for significant electrolyte abnormalities; and history of cardiac arrhythmia [see CONTRAINDICATIONS (4.1) and WARNINGS AND PRECAUTIONS (5.3)].
Instruct patients to report the onset of any conditions that put them at risk for significant electrolyte disturbances, hypokalemia in particular, including but not limited to the initiation of diuretic therapy or prolonged diarrhea. In addition, patients should be instructed to report symptoms such as dizziness, palpitations, or syncope to the prescriber [see WARNINGS AND PRECAUTIONS (5.3)].
Severe Cutaneous Adverse Reactions Instruct patients to report to their health care provider at the earliest onset any signs or symptoms that may be associated with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) or with severe cutaneous adverse reactions, such as Stevens-Johnson syndrome [see WARNINGS AND PRECAUTIONS (5.5)].
Distributor: Dr.Reddy’s Laboratories Inc.,
Princeton, NJ 08540
Made in India
|ZIPRASIDONE MESYLATE ziprasidone mesylate injection, powder, lyophilized, for solution|
|Labeler — HF Acquisition Co LLC, DBA HealthFirst (045657305)|
|Registrant — HF Acquisition Co LLC, DBA HealthFirst (045657305)|
|HF Acquisition Co LLC, DBA HealthFirst||045657305||relabel (51662-1564)|
Revised: 07/2021 HF Acquisition Co LLC, DBA HealthFirst
RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.